The characterization of such discrete AR-interacting motifs should enable development of small molecule drugs that bind to those sites and selectively target dysregulated growth signaling in prostate cancer, while avoiding the global side effects of androgen ablation. The gene discussed is AR; the disease is prostate cancer.